Saúde Pública/Medicina Humanitária

Opinião | Prevenção da transmissão do SARS-CoV-2 em ambientes de cuidados em saúde no contexto da variante Ômicron.

28 Jan, 2022 | 15:38h

Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant – JAMA

 

Comentário no Twitter

Our new piece in @JAMA_current

Transmission of #SARSCoV2 in healthcare settings is a serious concern

We outline three ways hospitals can better prepare for surges— mandating boosters, increasing frequency of testing, & upgrading to N95 maskshttps://t.co/2xRKdKPlhO pic.twitter.com/y0L4UzUNSo

— Abraar Karan (@AbraarKaran) January 24, 2022

 

---

Estudo randomizado | Terapia de observação eletrônica direta é não inferior à terapia de observação pessoal para garantir a adesão ao tratamento da tuberculose.

28 Jan, 2022 | 15:30h

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial – JAMA Network Open

 

Comentário no Twitter

In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266

— JAMA Network Open (@JAMANetworkOpen) January 20, 2022

 

---

Breve revisão ACP | Risco de reinfecção após contágio pelo SARS-CoV-2.

25 Jan, 2022 | 15:07h

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

 

Comentário no Twitter

Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo

— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022

 

---

OMS deixa de se opor aos reforços de vacina – recomenda a terceira dose da Pfizer para adultos e 2 doses de vacinas para crianças a partir de 5 anos de idade.

25 Jan, 2022 | 15:06h

WHO Drops Opposition to Boosters – Recommends Third Pfizer Jab for Adults & Two Vaccines for Children Ages 5 & Up – Health Policy Watch

Conteúdos relacionados:

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

---

Um estudo de caso-controle mostrou risco aumentado de miocardite após vacinação contra COVID-19 com vacina mRNA em comparação com vacina de vírus inativado.

25 Jan, 2022 | 15:04h

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study – Annals of Internal Medicine

Comunicado de imprensa: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

---

Avaliação inicial da gravidade clínica da variante Ômicron do SARS-CoV-2 na África do Sul.

25 Jan, 2022 | 15:02h

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study – The Lancet

Comentário: Omicron severity: milder but not mild – The Lancet

 

Comentário no Twitter

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in S. Africa, Lancet. Individuals with Omicron vs previous infections 80% lower odds of being admitted to hospital, 70% lower odds of severe disease than Deltahttps://t.co/528NWfKrDN

— Monica Gandhi MD, MPH (@MonicaGandhi9) January 23, 2022

 

---

[Preprint] Estudo de coorte | Risco reduzido de internação associado com infecção pela variante Ômicron do SARS-CoV-2 em relação à variante Delta.

25 Jan, 2022 | 15:01h

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study – SSRN / Preprints with The Lancet

Comentários:

Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post

Omicron has a 36% lower risk for hospitalization compared to Delta: Denmark study – Outbreak News Today

 

Comentário no Twitter

New Danish population-based cohort study confirms lower (36%, 95%CI 44%-25%) risk of hospitalization with Omicron compared with Delta.
The risk also seems to be reduced irrespective of vaccination status.

Pre-print can be found here: https://t.co/LfRrw1H3CY pic.twitter.com/Ql3zPyZyRE

— Anders Husby (@a_husby) January 20, 2022

 

---

[Preprint] A variante Ômicron do SARS-CoV-2 está associada com risco reduzido de internação e permanência em hospital, em comparação com a variante Delta.

25 Jan, 2022 | 14:59h

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) – medRxiv

 

Comentário no Twitter

In Portugal, Omicron hospitalizations were 75% reduced compared with Delta, risk adjusted. Vaccination reduced hospitalizations 84%, w/a booster 93%https://t.co/MvkfuF3mzx pic.twitter.com/zyk2INWNis

— Eric Topol (@EricTopol) January 23, 2022

 

---

COVID-19: endemia não significa que o risco acabou.

25 Jan, 2022 | 14:58h

COVID-19: endemic doesn’t mean harmless – Nature

---

Diretor geral da OMS | “Vamos conviver com a COVID em futuro previsível; mas podemos acabar com a fase aguda da pandemia este ano.”

25 Jan, 2022 | 14:57h

We Will be Living with COVID for Foreseeable Future; but We Can End Acute Phase of Pandemic this Year — WHO Director General – Health Policy Watch

---